Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| RxSight, Inc.RXST · Entity 1226 | Chief Operating Officer | September 05, 2026 | September 10, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
RxSight, Inc.
Report date September 05, 2026 · Filed September 10, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.00 · Expires 2031-07-30 | Direct | 0 |
Reported balance
After 2026-09-05 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-09-05 · Disposition to issuer · Disposed 98,367 · Balance 0 F1: On September 5, 2026, in connection with the Issuer's option exchange program, the Issuer exchanged the Reporting Person's outstanding option on a 1.33:1 basis with a post-exchange exercise price of $6.375 per share. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.95 · Expires 2033-03-08 | Direct | 0 |
Reported balance
After 2026-09-05 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-09-05 · Disposition to issuer · Disposed 120,000 · Balance 0 F3: On September 5, 2026, in connection with the Issuer's option exchange program, the Issuer exchanged the Reporting Person's outstanding option on a 1.15:1 basis with a post-exchange exercise price of $6.375 per share. F2: Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through each applicable date, one forty-eighth (1/48th) of the shares subject to the option shall vest each month following the Vesting Commencement Date on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month). "Vesting Commencement Date" shall mean March 9, 2023. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $56.07 · Expires 2034-03-03 | Direct | 0 |
Reported balance
After 2026-09-05 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-09-05 · Disposition to issuer · Disposed 92,200 · Balance 0 F5: On September 5, 2026, in connection with the Issuer's option exchange program, the Issuer exchanged the Reporting Person's outstanding option on a 1.55:1 basis with a post-exchange exercise price of $6.375 per share. F4: Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through each applicable date, one forty-eighth (1/48th) of the shares subject to the option shall vest each month following the Vesting Commencement Date on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month). "Vesting Commencement Date" shall mean March 4, 2024. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $46.24 · Expires 2034-08-06 | Direct | 0 |
Reported balance
After 2026-09-05 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-09-05 · Disposition to issuer · Disposed 50,000 · Balance 0 F5: On September 5, 2026, in connection with the Issuer's option exchange program, the Issuer exchanged the Reporting Person's outstanding option on a 1.55:1 basis with a post-exchange exercise price of $6.375 per share. F6: Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through each applicable date, one forty-eighth (1/48th) of the shares subject to the option shall vest each month following the Vesting Commencement Date on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month). "Vesting Commencement Date" shall mean August 7, 2024. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $28.21 · Expires 2035-02-26 | Direct | 0 |
Reported balance
After 2026-09-05 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-09-05 · Disposition to issuer · Disposed 125,000 · Balance 0 F1: On September 5, 2026, in connection with the Issuer's option exchange program, the Issuer exchanged the Reporting Person's outstanding option on a 1.33:1 basis with a post-exchange exercise price of $6.375 per share. F7: Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through each applicable date, one forty-eighth (1/48th) of the shares subject to the option shall vest each month following the Vesting Commencement Date on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month). "Vesting Commencement Date" shall mean February 27, 2025. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.38 · Expires 2033-09-04 | Direct | 73,960 |
Reported balance
After 2026-09-05 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-09-05 · Grant · Acquired 73,960 · Balance 73,960 F1: On September 5, 2026, in connection with the Issuer's option exchange program, the Issuer exchanged the Reporting Person's outstanding option on a 1.33:1 basis with a post-exchange exercise price of $6.375 per share. F8: Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through each applicable date, 25% of the shares subject to the option will vest on February 28, 2027 and the remaining 75% of the shares subject to the option will vest on August 31, 2027. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.38 · Expires 2033-09-04 | Direct | 104,347 |
Reported balance
After 2026-09-05 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2026-09-05 · Grant · Acquired 104,347 · Balance 104,347 F3: On September 5, 2026, in connection with the Issuer's option exchange program, the Issuer exchanged the Reporting Person's outstanding option on a 1.15:1 basis with a post-exchange exercise price of $6.375 per share. F9: Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through each applicable date, 25% of the 89,129 shares subject to the option will vest on February 28, 2027 and the remaining 75% of the 89,129 shares subject to the option will vest on August 31, 2027. Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through each applicable date, one twenty-fourth (1/24th) of the 15,218 shares subject to the option will vest on February 28, 2027 and in equal monthly installments thereafter. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.38 · Expires 2033-09-04 | Direct | 59,483 |
Reported balance
After 2026-09-05 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2026-09-05 · Grant · Acquired 59,483 · Balance 59,483 F5: On September 5, 2026, in connection with the Issuer's option exchange program, the Issuer exchanged the Reporting Person's outstanding option on a 1.55:1 basis with a post-exchange exercise price of $6.375 per share. F10: Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through each applicable date, 25% of the 37,177 shares subject to the option will vest on February 28, 2027 and the remaining 75% of the 37,177 shares subject to the option will vest on August 31, 2027. Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through each applicable date, one twenty-fourth (1/24th) of the 22,306 shares subject to the option will vest on February 28, 2027 and in equal monthly installments thereafter. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.38 · Expires 2033-09-04 | Direct | 32,258 |
Reported balance
After 2026-09-05 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2026-09-05 · Grant · Acquired 32,258 · Balance 32,258 F5: On September 5, 2026, in connection with the Issuer's option exchange program, the Issuer exchanged the Reporting Person's outstanding option on a 1.55:1 basis with a post-exchange exercise price of $6.375 per share. F11: Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through each applicable date, 25% of the 16,129 shares subject to the option will vest on February 28, 2027 and the remaining 75% of the 16,129 shares subject to the option will vest on August 31, 2027. Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through each applicable date, one twenty-fourth (1/24th) of the 16,129 shares subject to the option will vest on February 28, 2027 and in equal monthly installments thereafter. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.38 · Expires 2033-09-04 | Direct | 93,984 |
Reported balance
After 2026-09-05 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2026-09-05 · Grant · Acquired 93,984 · Balance 93,984 F1: On September 5, 2026, in connection with the Issuer's option exchange program, the Issuer exchanged the Reporting Person's outstanding option on a 1.33:1 basis with a post-exchange exercise price of $6.375 per share. F12: Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through each applicable date, 25% of the 35,244 shares subject to the option will vest on February 28, 2027 and the remaining 75% of the 35,244 shares subject to the option will vest on August 31, 2027. Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through each applicable date, one twenty-fourth (1/24th) of the 58,740 shares subject to the option will vest on February 28, 2027 and in equal monthly installments thereafter. |
Filing footnotes · ownership attribution and instrument terms
F1: On September 5, 2026, in connection with the Issuer's option exchange program, the Issuer exchanged the Reporting Person's outstanding option on a 1.33:1 basis with a post-exchange exercise price of $6.375 per share.
F2: Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through each applicable date, one forty-eighth (1/48th) of the shares subject to the option shall vest each month following the Vesting Commencement Date on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month). "Vesting Commencement Date" shall mean March 9, 2023.
F3: On September 5, 2026, in connection with the Issuer's option exchange program, the Issuer exchanged the Reporting Person's outstanding option on a 1.15:1 basis with a post-exchange exercise price of $6.375 per share.
F4: Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through each applicable date, one forty-eighth (1/48th) of the shares subject to the option shall vest each month following the Vesting Commencement Date on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month). "Vesting Commencement Date" shall mean March 4, 2024.
F5: On September 5, 2026, in connection with the Issuer's option exchange program, the Issuer exchanged the Reporting Person's outstanding option on a 1.55:1 basis with a post-exchange exercise price of $6.375 per share.
F6: Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through each applicable date, one forty-eighth (1/48th) of the shares subject to the option shall vest each month following the Vesting Commencement Date on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month). "Vesting Commencement Date" shall mean August 7, 2024.
F7: Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through each applicable date, one forty-eighth (1/48th) of the shares subject to the option shall vest each month following the Vesting Commencement Date on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month). "Vesting Commencement Date" shall mean February 27, 2025.
F8: Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through each applicable date, 25% of the shares subject to the option will vest on February 28, 2027 and the remaining 75% of the shares subject to the option will vest on August 31, 2027.
F9: Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through each applicable date, 25% of the 89,129 shares subject to the option will vest on February 28, 2027 and the remaining 75% of the 89,129 shares subject to the option will vest on August 31, 2027. Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through each applicable date, one twenty-fourth (1/24th) of the 15,218 shares subject to the option will vest on February 28, 2027 and in equal monthly installments thereafter.
F10: Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through each applicable date, 25% of the 37,177 shares subject to the option will vest on February 28, 2027 and the remaining 75% of the 37,177 shares subject to the option will vest on August 31, 2027. Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through each applicable date, one twenty-fourth (1/24th) of the 22,306 shares subject to the option will vest on February 28, 2027 and in equal monthly installments thereafter.
F11: Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through each applicable date, 25% of the 16,129 shares subject to the option will vest on February 28, 2027 and the remaining 75% of the 16,129 shares subject to the option will vest on August 31, 2027. Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through each applicable date, one twenty-fourth (1/24th) of the 16,129 shares subject to the option will vest on February 28, 2027 and in equal monthly installments thereafter.
F12: Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through each applicable date, 25% of the 35,244 shares subject to the option will vest on February 28, 2027 and the remaining 75% of the 35,244 shares subject to the option will vest on August 31, 2027. Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through each applicable date, one twenty-fourth (1/24th) of the 58,740 shares subject to the option will vest on February 28, 2027 and in equal monthly installments thereafter.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 17, 2024 Filed Sep 18, 2024 20:41 UTC | RxSight, Inc. RXST · Entity 1226 | Exercise / conversionStock Option (right to buy) · Derivative | 3,100 | $0.00 Strike: $15.08 | $0.00 |
DisclosureSEC source: 0000950170-24-107829 · ownership.xml · derivative · entry 4 Goldshleger Ilya · CIK 0001874147 · See remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 112,107 Underlying: Common Stock · 3,100 shares Expires 2030-04-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2015 Equity Incentive Plan, as amended) through each applicable date, one forty-eighth (1/48th) of the shares subject to the option shall vest each month following the Vesting Commencement Date on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month). "Vesting Commencement Date" shall mean April 23, 2020. Read SEC document |
| September 17, 2024 Filed Sep 18, 2024 20:41 UTC | RxSight, Inc. RXST · Entity 1226 | SaleCommon Stock | 3,100 | $56.11 | $173,944.10 |
DisclosureSEC source: 0000950170-24-107829 · ownership.xml · nonDerivative · entry 2 Goldshleger Ilya · CIK 0001874147 · See remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 42,246 F1 · kind: The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted on June 3, 2024 by the Reporting Person. F2 · price: Represents the weighted average share price of an aggregate total of 3,100 shares sold in the price range of $55.85 to $56.37 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| September 17, 2024 Filed Sep 18, 2024 20:41 UTC | RxSight, Inc. RXST · Entity 1226 | Exercise / conversionCommon Stock | 3,100 | $15.08 | $46,748.00 |
DisclosureSEC source: 0000950170-24-107829 · ownership.xml · nonDerivative · entry 1 Goldshleger Ilya · CIK 0001874147 · See remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 45,346 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 07, 2024 Filed Aug 8, 2024 20:16 UTC | RxSight, Inc. RXST · Entity 1226 | GrantStock Option (right to buy) · Derivative | 50,000 | $0.00 Strike: $46.24 | $0.00 |
DisclosureSEC source: 0000950170-24-094017 · ownership.xml · derivative · entry 1 Goldshleger Ilya · CIK 0001874147 · See remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2034-08-06 F1 · derivative.exercise_date: Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through each applicable date, one forty-eighth (1/48th) of the shares subject to the option shall vest each month following the Vesting Commencement Date on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month). "Vesting Commencement Date" shall mean Augusts 7, 2024. Read SEC document |
| August 05, 2024 Filed Aug 6, 2024 20:19 UTC | RxSight, Inc. RXST · Entity 1226 | SaleCommon Stock | 1,173 | $39.73 | $46,602.47 |
DisclosureSEC source: 0000950170-24-091847 · ownership.xml · nonDerivative · entry 6 Goldshleger Ilya · CIK 0001874147 · See remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 42,246 F1 · kind: The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted on September 13, 2023 by the Reporting Person. F7 · price: Represents the weighted average share price of an aggregate total of 1,173 shares sold in the price range of $39.45 to $40.095 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| August 05, 2024 Filed Aug 6, 2024 20:19 UTC | RxSight, Inc. RXST · Entity 1226 | SaleCommon Stock | 1,827 | $39.04 | $71,331.38 |
DisclosureSEC source: 0000950170-24-091847 · ownership.xml · nonDerivative · entry 5 Goldshleger Ilya · CIK 0001874147 · See remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 43,419 F1 · kind: The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted on September 13, 2023 by the Reporting Person. F6 · price: Represents the weighted average share price of an aggregate total of 1,827 shares sold in the price range of $38.43 to $39.42 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| August 05, 2024 Filed Aug 6, 2024 20:19 UTC | RxSight, Inc. RXST · Entity 1226 | SaleCommon Stock | 1,913 | $39.51 | $75,587.99 |
DisclosureSEC source: 0000950170-24-091847 · ownership.xml · nonDerivative · entry 4 Goldshleger Ilya · CIK 0001874147 · See remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 45,246 F1 · kind: The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted on September 13, 2023 by the Reporting Person. F5 · price: Represents the weighted average share price of an aggregate total of 1,913 shares sold in the price range of $39.13 to $40.095 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| August 05, 2024 Filed Aug 6, 2024 20:19 UTC | RxSight, Inc. RXST · Entity 1226 | SaleCommon Stock | 1,087 | $38.83 | $42,207.01 |
DisclosureSEC source: 0000950170-24-091847 · ownership.xml · nonDerivative · entry 3 Goldshleger Ilya · CIK 0001874147 · See remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 47,159 F1 · kind: The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted on September 13, 2023 by the Reporting Person. F4 · price: Represents the weighted average share price of an aggregate total of 1,087 shares sold in the price range of $38.00 to $38.99 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| August 05, 2024 Filed Aug 6, 2024 20:19 UTC | RxSight, Inc. RXST · Entity 1226 | SaleCommon Stock | 1,855 | $39.43 | $73,134.86 |
DisclosureSEC source: 0000950170-24-091847 · ownership.xml · nonDerivative · entry 2 Goldshleger Ilya · CIK 0001874147 · See remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 48,246 F1 · kind: The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted on September 13, 2023 by the Reporting Person. F3 · price: Represents the weighted average share price of an aggregate total of 1,855 shares sold in the price range of $39.11 to $40.095 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| August 05, 2024 Filed Aug 6, 2024 20:19 UTC | RxSight, Inc. RXST · Entity 1226 | SaleCommon Stock | 1,145 | $38.80 | $44,427.26 |
DisclosureSEC source: 0000950170-24-091847 · ownership.xml · nonDerivative · entry 1 Goldshleger Ilya · CIK 0001874147 · See remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 50,101 F1 · kind: The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted on September 13, 2023 by the Reporting Person. F2 · price: Represents the weighted average share price of an aggregate total of 1,145 shares sold in the price range of $38.00 to $38.99 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| May 17, 2024 Filed May 20, 2024 20:56 UTC | RxSight, Inc. RXST · Entity 1226 | Exercise / conversionStock Option (right to buy) · Derivative | 4,264 | $0.00 Strike: $4.34 | $0.00 |
DisclosureSEC source: 0000950170-24-062511 · ownership.xml · derivative · entry 7 Goldshleger Ilya · CIK 0001874147 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,416 Underlying: Common Stock · 4,264 shares Expires 2026-10-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 17, 2024 Filed May 20, 2024 20:56 UTC | RxSight, Inc. RXST · Entity 1226 | Exercise / conversionStock Option (right to buy) · Derivative | 4,840 | $0.00 Strike: $4.13 | $0.00 |
DisclosureSEC source: 0000950170-24-062511 · ownership.xml · derivative · entry 6 Goldshleger Ilya · CIK 0001874147 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,840 shares Expires 2026-07-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 17, 2024 Filed May 20, 2024 20:56 UTC | RxSight, Inc. RXST · Entity 1226 | Exercise / conversionStock Option (right to buy) · Derivative | 15,667 | $0.00 Strike: $3.93 | $0.00 |
DisclosureSEC source: 0000950170-24-062511 · ownership.xml · derivative · entry 5 Goldshleger Ilya · CIK 0001874147 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,667 shares Expires 2025-10-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 17, 2024 Filed May 20, 2024 20:56 UTC | RxSight, Inc. RXST · Entity 1226 | Exercise / conversionCommon Stock | 4,264 | $4.34 | $18,505.76 |
DisclosureSEC source: 0000950170-24-062511 · ownership.xml · nonDerivative · entry 3 Goldshleger Ilya · CIK 0001874147 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 51,246 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 17, 2024 Filed May 20, 2024 20:56 UTC | RxSight, Inc. RXST · Entity 1226 | Exercise / conversionCommon Stock | 4,840 | $4.13 | $19,989.20 |
DisclosureSEC source: 0000950170-24-062511 · ownership.xml · nonDerivative · entry 2 Goldshleger Ilya · CIK 0001874147 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 46,982 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 17, 2024 Filed May 20, 2024 20:56 UTC | RxSight, Inc. RXST · Entity 1226 | Exercise / conversionCommon Stock | 15,667 | $3.93 | $61,571.31 |
DisclosureSEC source: 0000950170-24-062511 · ownership.xml · nonDerivative · entry 1 Goldshleger Ilya · CIK 0001874147 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 42,142 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 04, 2024 Filed Mar 6, 2024 21:25 UTC | RxSight, Inc. RXST · Entity 1226 | GrantStock Option (right to buy) · Derivative | 92,200 | $0.00 Strike: $56.07 | $0.00 |
DisclosureSEC source: 0000950170-24-027184 · ownership.xml · derivative · entry 1 Goldshleger Ilya · CIK 0001874147 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 92,200 Underlying: Common Stock · 92,200 shares Expires 2034-03-03 F1 · derivative.exercise_date: Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through each applicable date, one forty-eighth (1/48th) of the shares subject to the option shall vest each month following the Vesting Commencement Date on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month). "Vesting Commencement Date" shall mean March 4, 2024. Read SEC document |
| February 16, 2024 Filed Feb 16, 2024 22:00 UTC | RxSight, Inc. RXST · Entity 1226 | Exercise / conversionStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $23.04 | $0.00 |
DisclosureSEC source: 0000950170-24-016515 · ownership.xml · derivative · entry 12 Goldshleger Ilya · CIK 0001874147 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires 2029-04-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 16, 2024 Filed Feb 16, 2024 22:00 UTC | RxSight, Inc. RXST · Entity 1226 | SaleCommon Stock | 5,000 | $56.00 | $280,000.00 |
DisclosureSEC source: 0000950170-24-016515 · ownership.xml · nonDerivative · entry 8 Goldshleger Ilya · CIK 0001874147 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 26,475 F1 · kind: The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted on September 13, 2023 by the Reporting Person. Read SEC document |
| February 16, 2024 Filed Feb 16, 2024 22:00 UTC | RxSight, Inc. RXST · Entity 1226 | SaleCommon Stock | 5,000 | $55.00 | $275,000.00 |
DisclosureSEC source: 0000950170-24-016515 · ownership.xml · nonDerivative · entry 7 Goldshleger Ilya · CIK 0001874147 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 31,475 F1 · kind: The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted on September 13, 2023 by the Reporting Person. Read SEC document |
| February 16, 2024 Filed Feb 16, 2024 22:00 UTC | RxSight, Inc. RXST · Entity 1226 | Exercise / conversionCommon Stock | 10,000 | $23.04 | $230,400.00 |
DisclosureSEC source: 0000950170-24-016515 · ownership.xml · nonDerivative · entry 6 Goldshleger Ilya · CIK 0001874147 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 36,475 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 15, 2024 Filed Feb 16, 2024 22:00 UTC | RxSight, Inc. RXST · Entity 1226 | Exercise / conversionStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $23.04 | $0.00 |
DisclosureSEC source: 0000950170-24-016515 · ownership.xml · derivative · entry 11 Goldshleger Ilya · CIK 0001874147 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2029-04-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 15, 2024 Filed Feb 16, 2024 22:00 UTC | RxSight, Inc. RXST · Entity 1226 | SaleCommon Stock | 5,000 | $54.00 | $270,000.00 |
DisclosureSEC source: 0000950170-24-016515 · ownership.xml · nonDerivative · entry 5 Goldshleger Ilya · CIK 0001874147 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 26,475 F1 · kind: The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted on September 13, 2023 by the Reporting Person. Read SEC document |
| February 15, 2024 Filed Feb 16, 2024 22:00 UTC | RxSight, Inc. RXST · Entity 1226 | SaleCommon Stock | 5,000 | $53.00 | $265,000.00 |
DisclosureSEC source: 0000950170-24-016515 · ownership.xml · nonDerivative · entry 4 Goldshleger Ilya · CIK 0001874147 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 31,475 F1 · kind: The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted on September 13, 2023 by the Reporting Person. Read SEC document |
| February 15, 2024 Filed Feb 16, 2024 22:00 UTC | RxSight, Inc. RXST · Entity 1226 | Exercise / conversionCommon Stock | 10,000 | $23.04 | $230,400.00 |
DisclosureSEC source: 0000950170-24-016515 · ownership.xml · nonDerivative · entry 3 Goldshleger Ilya · CIK 0001874147 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 36,475 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 14, 2024 Filed Feb 16, 2024 22:00 UTC | RxSight, Inc. RXST · Entity 1226 | Exercise / conversionStock Option (right to buy) · Derivative | 5,000 | $0.00 Strike: $23.04 | $0.00 |
DisclosureSEC source: 0000950170-24-016515 · ownership.xml · derivative · entry 10 Goldshleger Ilya · CIK 0001874147 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 5,000 shares Expires 2029-04-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 14, 2024 Filed Feb 16, 2024 22:00 UTC | RxSight, Inc. RXST · Entity 1226 | SaleCommon Stock | 5,000 | $52.00 | $260,000.00 |
DisclosureSEC source: 0000950170-24-016515 · ownership.xml · nonDerivative · entry 2 Goldshleger Ilya · CIK 0001874147 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 26,475 F1 · kind: The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted on September 13, 2023 by the Reporting Person. Read SEC document |
| February 14, 2024 Filed Feb 16, 2024 22:00 UTC | RxSight, Inc. RXST · Entity 1226 | Exercise / conversionCommon Stock | 5,000 | $23.04 | $115,200.00 |
DisclosureSEC source: 0000950170-24-016515 · ownership.xml · nonDerivative · entry 1 Goldshleger Ilya · CIK 0001874147 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 31,475 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 09, 2024 Filed Feb 12, 2024 23:02 UTC | RxSight, Inc. RXST · Entity 1226 | Exercise / conversionStock Option (right to buy) · Derivative | 5,000 | $0.00 Strike: $23.04 | $0.00 |
DisclosureSEC source: 0000950170-24-014006 · ownership.xml · derivative · entry 7 Goldshleger Ilya · CIK 0001874147 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 5,000 shares Expires 2029-04-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 09, 2024 Filed Feb 12, 2024 23:02 UTC | RxSight, Inc. RXST · Entity 1226 | Exercise / conversionStock Option (right to buy) · Derivative | 5,365 | $0.00 Strike: $18.90 | $0.00 |
DisclosureSEC source: 0000950170-24-014006 · ownership.xml · derivative · entry 6 Goldshleger Ilya · CIK 0001874147 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,995 Underlying: Common Stock · 5,365 shares Expires 2028-07-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 09, 2024 Filed Feb 12, 2024 23:02 UTC | RxSight, Inc. RXST · Entity 1226 | SaleCommon Stock | 5,000 | $51.00 | $255,000.00 |
DisclosureSEC source: 0000950170-24-014006 · ownership.xml · nonDerivative · entry 4 Goldshleger Ilya · CIK 0001874147 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 26,475 F1 · kind: The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted on September 13, 2023 by the Reporting Person. Read SEC document |
| February 09, 2024 Filed Feb 12, 2024 23:02 UTC | RxSight, Inc. RXST · Entity 1226 | SaleCommon Stock | 5,365 | $50.50 | $270,938.94 |
DisclosureSEC source: 0000950170-24-014006 · ownership.xml · nonDerivative · entry 3 Goldshleger Ilya · CIK 0001874147 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 31,475 F1 · kind: The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted on September 13, 2023 by the Reporting Person. F2 · price: Represents the weighted average share price of an aggregate total of 5,365 shares sold in the price range of $50.50 to $50.54 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| February 09, 2024 Filed Feb 12, 2024 23:02 UTC | RxSight, Inc. RXST · Entity 1226 | Exercise / conversionCommon Stock | 5,000 | $23.04 | $115,200.00 |
DisclosureSEC source: 0000950170-24-014006 · ownership.xml · nonDerivative · entry 2 Goldshleger Ilya · CIK 0001874147 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 36,840 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 09, 2024 Filed Feb 12, 2024 23:02 UTC | RxSight, Inc. RXST · Entity 1226 | Exercise / conversionCommon Stock | 5,365 | $18.90 | $101,398.50 |
DisclosureSEC source: 0000950170-24-014006 · ownership.xml · nonDerivative · entry 1 Goldshleger Ilya · CIK 0001874147 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 31,840 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 01, 2024 Filed Feb 2, 2024 21:47 UTC | RxSight, Inc. RXST · Entity 1226 | Exercise / conversionStock Option (right to buy) · Derivative | 590 | $0.00 Strike: $23.04 | $0.00 |
DisclosureSEC source: 0000950170-24-010565 · ownership.xml · derivative · entry 8 Goldshleger Ilya · CIK 0001874147 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 590 shares Expires 2029-04-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 01, 2024 Filed Feb 2, 2024 21:47 UTC | RxSight, Inc. RXST · Entity 1226 | Exercise / conversionStock Option (right to buy) · Derivative | 6,539 | $0.00 Strike: $18.90 | $0.00 |
DisclosureSEC source: 0000950170-24-010565 · ownership.xml · derivative · entry 7 Goldshleger Ilya · CIK 0001874147 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,981 Underlying: Common Stock · 6,539 shares Expires 2028-01-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 01, 2024 Filed Feb 2, 2024 21:47 UTC | RxSight, Inc. RXST · Entity 1226 | SaleCommon Stock | 590 | $50.00 | $29,500.00 |
DisclosureSEC source: 0000950170-24-010565 · ownership.xml · nonDerivative · entry 5 Goldshleger Ilya · CIK 0001874147 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 26,475 F1 · kind: The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted on September 13, 2023 by the Reporting Person. Read SEC document |
| February 01, 2024 Filed Feb 2, 2024 21:47 UTC | RxSight, Inc. RXST · Entity 1226 | SaleCommon Stock | 3,000 | $49.50 | $148,500.00 |
DisclosureSEC source: 0000950170-24-010565 · ownership.xml · nonDerivative · entry 4 Goldshleger Ilya · CIK 0001874147 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 27,065 F1 · kind: The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted on September 13, 2023 by the Reporting Person. Read SEC document |
| February 01, 2024 Filed Feb 2, 2024 21:47 UTC | RxSight, Inc. RXST · Entity 1226 | SaleCommon Stock | 3,539 | $49.00 | $173,411.00 |
DisclosureSEC source: 0000950170-24-010565 · ownership.xml · nonDerivative · entry 3 Goldshleger Ilya · CIK 0001874147 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 30,065 F1 · kind: The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted on September 13, 2023 by the Reporting Person. Read SEC document |
| February 01, 2024 Filed Feb 2, 2024 21:47 UTC | RxSight, Inc. RXST · Entity 1226 | Exercise / conversionCommon Stock | 590 | $23.04 | $13,593.60 |
DisclosureSEC source: 0000950170-24-010565 · ownership.xml · nonDerivative · entry 2 Goldshleger Ilya · CIK 0001874147 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 33,604 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 01, 2024 Filed Feb 2, 2024 21:47 UTC | RxSight, Inc. RXST · Entity 1226 | Exercise / conversionCommon Stock | 6,539 | $18.90 | $123,587.10 |
DisclosureSEC source: 0000950170-24-010565 · ownership.xml · nonDerivative · entry 1 Goldshleger Ilya · CIK 0001874147 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 33,014 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 22, 2024 Filed Jan 23, 2024 00:48 UTC | RxSight, Inc. RXST · Entity 1226 | Exercise / conversionStock Option (right to buy) · Derivative | 5,000 | $0.00 Strike: $18.90 | $0.00 |
DisclosureSEC source: 0000950170-24-006198 · ownership.xml · derivative · entry 4 Goldshleger Ilya · CIK 0001874147 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 9,360 Underlying: Common Stock · 5,000 shares Expires 2028-07-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 22, 2024 Filed Jan 23, 2024 00:48 UTC | RxSight, Inc. RXST · Entity 1226 | SaleCommon Stock | 5,000 | $48.00 | $240,000.00 |
DisclosureSEC source: 0000950170-24-006198 · ownership.xml · nonDerivative · entry 2 Goldshleger Ilya · CIK 0001874147 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 26,475 F1 · kind: The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted on September 13, 2023 by the Reporting Person. Read SEC document |
| January 22, 2024 Filed Jan 23, 2024 00:48 UTC | RxSight, Inc. RXST · Entity 1226 | Exercise / conversionCommon Stock | 5,000 | $18.90 | $94,500.00 |
DisclosureSEC source: 0000950170-24-006198 · ownership.xml · nonDerivative · entry 1 Goldshleger Ilya · CIK 0001874147 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 31,475 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 09, 2024 Filed Jan 10, 2024 22:29 UTC | RxSight, Inc. RXST · Entity 1226 | Exercise / conversionStock Option (right to buy) · Derivative | 5,000 | $0.00 Strike: $18.90 | $0.00 |
DisclosureSEC source: 0000950170-24-003682 · ownership.xml · derivative · entry 4 Goldshleger Ilya · CIK 0001874147 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 14,360 Underlying: Common Stock · 5,000 shares Expires 2028-07-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 09, 2024 Filed Jan 10, 2024 22:29 UTC | RxSight, Inc. RXST · Entity 1226 | SaleCommon Stock | 5,000 | $47.00 | $235,000.00 |
DisclosureSEC source: 0000950170-24-003682 · ownership.xml · nonDerivative · entry 2 Goldshleger Ilya · CIK 0001874147 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 26,475 F1 · kind: The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted on September 13, 2023 by the Reporting Person. Read SEC document |
| January 09, 2024 Filed Jan 10, 2024 22:29 UTC | RxSight, Inc. RXST · Entity 1226 | Exercise / conversionCommon Stock | 5,000 | $18.90 | $94,500.00 |
DisclosureSEC source: 0000950170-24-003682 · ownership.xml · nonDerivative · entry 1 Goldshleger Ilya · CIK 0001874147 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 31,475 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 08, 2024 Filed Jan 9, 2024 21:05 UTC | RxSight, Inc. RXST · Entity 1226 | Exercise / conversionStock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $15.08 | $0.00 |
DisclosureSEC source: 0000950170-24-003327 · ownership.xml · derivative · entry 6 Goldshleger Ilya · CIK 0001874147 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 115,207 Underlying: Common Stock · 15,000 shares Expires 2030-04-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2015 Equity Incentive Plan, as amended) through each applicable date, one forty-eighth (1/48th) of the shares subject to the option shall vest each month following the Vesting Commencement Date on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month). "Vesting Commencement Date" shall mean April 23, 2020. Read SEC document |
| January 08, 2024 Filed Jan 9, 2024 21:05 UTC | RxSight, Inc. RXST · Entity 1226 | SaleCommon Stock | 5,000 | $45.00 | $225,000.00 |
DisclosureSEC source: 0000950170-24-003327 · ownership.xml · nonDerivative · entry 4 Goldshleger Ilya · CIK 0001874147 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 26,475 F1 · kind: The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted on September 13, 2023 by the Reporting Person. Read SEC document |
| January 08, 2024 Filed Jan 9, 2024 21:05 UTC | RxSight, Inc. RXST · Entity 1226 | SaleCommon Stock | 5,000 | $43.00 | $215,000.00 |
DisclosureSEC source: 0000950170-24-003327 · ownership.xml · nonDerivative · entry 3 Goldshleger Ilya · CIK 0001874147 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 31,475 F1 · kind: The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted on September 13, 2023 by the Reporting Person. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.